LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a company with a next generation, ultra-sensitive digital platform that advances precision health, today announced the commencement of the initial public offering of shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “Commission”). The offering consists of 3,340,000 shares of common stock being offered by the Company. In addition, the Company is expected to grant the underwriters a 30-day option to purchase up to an additional 501,000 shares of common stock at the public offering price, less the underwriting discount. The current expected initial public offering price is between $14.00 and $16.00 per share. Quanterix plans to list its common stock on The NASDAQ Global Market under the ticker symbol “QTRX.”
The Company intends to use the net proceeds from the offering: (1) to expand its life sciences commercial operations to grow and support the installed base of its products among life sciences research customers; (2) to improve and update its Simoa technology and instruments and to develop additional assays, including assays for nucleic acid detection; (3) to support the launch of its new Quanterix SR-X instrument; (4) to potentially move into a larger corporate headquarters to support the expected increase in its employee base and an increase in its manufacturing footprint; (5) to pursue regulatory approvals or clearances to develop instruments, assay kits and consumables in areas outside of life science research, including potentially LDTs, IVD tests and other markets, and, subject to the receipt of such necessary regulatory approvals or clearances, to develop such instruments, assay kits and consumables; (6) to potentially pursue acquisitions or other business development opportunities; and (7) for working capital and other general corporate purposes.
J.P. Morgan Securities LLC, Leerink Partners LLC and Cowen and Company, LLC will serve as joint book-running managers for the offering. BTIG, LLC and Evercore Group L.L.C. will serve as co-managers.
This offering will be made only by means of a prospectus. A copy of the preliminary prospectus can be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email at firstname.lastname@example.org; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by calling (631) 274-2806 or by faxing (631) 254-7140.
The registration statement relating to these securities has been filed with the Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
This press release contains certain forward-looking statements, including statements with regard to Quanterix Corporation’s proposed initial public offering and use of the proceeds from the initial public offering. Words such as “expects,” “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the initial public offering discussed above will be completed on the terms described. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, failure of customary closing conditions and the risk factors and other matters set forth in the prospectus included in the registration statement, in the form last filed with the Commission. Quanterix undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Quanterix is a company digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The Company was established in 2007 and is located in Lexington, Massachusetts.
Lauren Kaufman, 617-502-4300